$AVEO Ms. Hsu: Do you think tivozanib is ready for primetime? Would you use it in the clinic? Dr. Pal: Tivozanib is an agent that I think is ideally placed, consistent with the recent press release from AVEO, in the refractory setting in patients with advanced renal cell carcinoma. There are perhaps more potent and active agents to use in the front-line setting such as cabozantinib and either alone or in combination with immunotherapeutic agents on the basis of ongoing studies. I will say that tivozanib, however, based on its toxicity profile, represents a very reasonable option to use in the context of patients with more advanced disease. This is a point in time in which patients may potentially prioritize quality of life.